Maipl Therapeutics Reports Preclinical Progress for MA-4604, a Novel Oral Non-Hormonal Treatment of Endometriosis Newswise
Endometriosis is a chronic inflammatory disorder affecting approximately 10% of reproductive-age women, yet non-hormonal therapeutic options remain limited. This study investigates the role of the TLR4/NF-κB/NLRP3 inflammasome axis in endometriosis …
Endometriosis is a chronic, estrogen-dependent inflammatory disease including aberrant local steroidogenesis, inflammation, angiogenesis, oxidative stress, and prostaglandin-mediated pain. Given the elevated adrenergic receptor expression in endometriotic lesions and the potential …
Growing evidence highlights the role of microbiota, including those of the gut, reproductive tract, and endometrial tissue, as critical functional drivers in the pathogenesis of endometriosis (EM). Studies have revealed …
Adenomyosis is a prevalent disorder of the archimetra, historically conflated with endometriosis but possessing a unique pathobiological trajectory. This review synthesises current molecular evidence to propose a unified mechanistic framework …
Gesynta Pharma Doses First Patient in Phase 2 Trial of Non-Hormonal, Non-Opioid Endometriosis Treatment Femtech Insider
Gesynta Pharma Doses First Patient in Phase 2 Trial of Non-Hormonal, Non-Opioid Endometriosis Treatment femtechinsider.com
Endometriosis, PCOS, adenomyosis, and dysmenorrhea are major illnesses. Hormonal as well as non-hormonal treatments were evaluated for COCs, progestins, GnRH analogues, LNG-IUS, relugolix, and adjunctive therapies. These treatments resulted in …
Hope Medicine Doses First Patient in Phase III Trial of Non-Hormonal Endometriosis Treatment Femtech Insider
EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis BioSpace